基因组预测转移导向治疗联合或不联合雄激素剥夺治疗的应答
本研究探讨转移导向治疗(MDT)联合或不联合雄激素剥夺治疗(ADT)在寡转移性去势敏感性前列腺癌(omCSPC)中的作用,并分析基因组改变对MDT应答的预后和预测价值。发现TP53、BRCA1/2、ATM和Rb1高危突变是omCSPC的不良预后标志,且携带这些突变的患者从联合ADT中获益更大。
要点
- TP53、BRCA1/2、ATM和Rb1高危突变是omCSPC不良预后标志。
- 携带高危突变患者从MDT联合ADT中获益更大,提示可指导治疗强化。
- 基因组生物标志物可能有助于omCSPC的治疗个体化。
核心结论
- TP53、BRCA1/2、ATM和Rb1高危突变是omCSPC的不良预后标志,并可预测MDT联合ADT的获益。
主要发现
- 高危突变(TP53、BRCA1/2、ATM、Rb1)与omCSPC不良预后相关。
- 携带高危突变的患者接受MDT联合ADT比单用MDT获益更大。
临床怎么用
- 对omCSPC患者可考虑检测TP53、BRCA1/2、ATM和Rb1突变以指导治疗个体化。
- 携带高危突变者可能从MDT联合ADT的治疗强化中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.
引用
- Sutera P, Van der Eecken K, Song Y, et al. Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy. Eur Urol Oncol. 2025. PMID: 40976747. doi:10.1016/j.euo.2025.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。